Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ 3 Reasons Growth Investors Will Love Argan (AGX) (Zacks) +++ ARGAN Aktie +8,70%

ANGIODYNAMICS Aktie

 >ANGIODYNAMICS Aktienkurs 
11.75 EUR    (TradegateBSX)
Ask: 11.8 EUR / 280 Stück
Bid: 11.7 EUR / 2855 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>ANGIODYNAMICS Performance
1 Woche: +10,8%
1 Monat: +15,8%
3 Monate: +19,9%
6 Monate: +5,4%
1 Jahr: +29,1%
laufendes Jahr: +6,8%
>ANGIODYNAMICS Aktie
Name:  ANGIODYNAMICS INC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US03475V1017 / A0B9A5
Symbol/ Ticker:  UG2 (Frankfurt) / ANGO (NASDAQ)
Kürzel:  FRA:UG2, ETR:UG2, UG2:GR, NASDAQ:ANGO
Index:  -
Webseite:  https://www.angiodynamics..
Profil:  AngioDynamics Inc. is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices for treating peripheral vascular disease, oncology, and surgical applications in the United States and internationally...
>Volltext..
Marktkapitalisierung:  486.36 Mio. EUR
Unternehmenswert:  464.02 Mio. EUR
Umsatz:  275.58 Mio. EUR
EBITDA:  2.41 Mio. EUR
Nettogewinn:  -27.57 Mio. EUR
Gewinn je Aktie:  -0.67 EUR
Schulden:  10.01 Mio. EUR
Liquide Mittel:  33.21 Mio. EUR
Operativer Cashflow:  3.31 Mio. EUR
Bargeldquote:  0.57
Umsatzwachstum:  -2.76%
Gewinnwachstum:  33.41%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ANGIODYNAMICS
Letzte Datenerhebung:  27.06.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 41.32 Mio. St.
Frei handelbar: 88.46%
Rückkaufquote: -0.17%
Mitarbeiter: 675
Umsatz/Mitarb.: 0.38 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 34.84%
Bewertung:
KGV: -
KGV lG: -
KUV: 1.73
KBV: 3.27
PEG-Ratio: -
EV/EBITDA: 192.72
Rentabilität:
Bruttomarge: 50.93%
Gewinnmarge: -10%
Operative Marge: -6.52%
Managementeffizenz:
Gesamtkaprendite: -11.5%
Eigenkaprendite: -17.47%
>Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Onkologie/ Krebs- Behandlung
 
23.06.26 - 20:30
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now (Zacks)
 
ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures....
18.06.26 - 17:30
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study (Zacks)
 
AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment....
22.05.26 - 17:30
Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High? (Zacks)
 
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 50.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
06.05.26 - 17:31
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet (Zacks)
 
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
20.04.26 - 17:30
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here′s is How to Trade (Zacks)
 
The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....
08.04.26 - 19:45
AngioDynamics (ANGO) Upgraded to Buy: Here′s Why (Zacks)
 
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
06.04.26 - 19:45
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down (Zacks)
 
AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips....
02.04.26 - 16:15
AngioDynamics signals FY2026 adjusted EBITDA of $10M-$12M while raising net sales guidance to $313.5M-$315.5M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.04.26 - 14:54
AngioDynamics übertrifft Gewinnprognose, Aktie gibt dennoch nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.04.26 - 14:30
AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
 
AngioDynamics (ANGO) delivered earnings and revenue surprises of +33.33% and +1.35%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?...
02.04.26 - 12:09
AngioDynamics Non-GAAP EPS of -$0.07 beats by $0.04, revenue of $78.42M beats by $1.65M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.04.26 - 12:06
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability (Business Wire)
 
Med Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted EBITDA LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights    Quarter Ended February 28, 2026  Pro Forma* YoY Growth Net Sales  $78.4 million  8.9% Med Tech Net Sales  $37.3 million  19.0% Med Device Net Sales  $41.1 million  1.1% GAAP gross margin of 52.9% GAAP loss per share of $0.19 Adjusted loss per share of $0.07 Adjusted EBITDA of $1.8 million Ended fiscal 2026 third quarter with $37.8 million in cash, in line with expectation...
02.04.26 - 11:24
Acuity, Lindsay And 3 Stocks To Watch Heading Into Thursday (Benzinga)
 
U.S. stock futures trading lower, Acuity and Visionary Holdings report strong earnings, Lindsay Corp expected to post earnings, Globalstar shares jump after Amazon acquisition talks, AngioDynamics expected to report loss. Importance Rank:  1 read more...
29.03.26 - 15:33
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
19.03.26 - 13:06
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026 (Business Wire)
 
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A recording of the call will also be available, until Thursday, April 9, 2026 at 11:59 PM ET. To hear this recording, dial 1-84...
11.03.26 - 18:45
Reasons to Add AngioDynamics Stock to Your Portfolio for Now (Zacks)
 
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer and broad Med Tech growth supporting margins....
09.03.26 - 23:30
AngioDynamics auf Leerink-Konferenz: Strategischer Schwenk zu technologiegetriebenem Wachstum (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
23.02.26 - 20:30
ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation (Zacks)
 
AngioDynamics expands NanoKnife's EU indications to liver, pancreas, kidney and prostate tumors, broadening its oncology reach and growth runway....
06.02.26 - 17:30
Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect? (Zacks)
 
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
05.02.26 - 19:01
AngioDynamics (ANGO) Down 3.9% Since Last Earnings Report: Can It Rebound? (Zacks)
 
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: O, der Einfall war kindisch, aber göttlich schön! - Friedrich Johann Christoph Schiller
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!